CORT
Corcept Therapeutics Incorporated
CORT has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over CORT overall, supported by stronger valuation and stronger fundamentals.
CORT Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
CORT's revenue, profitability, cash flow and balance sheet are all currently strong.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
CORT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 17x | $73.71 | — |
| Cheap | 22x | $27.59 | -63% |
| Fair | 29x | $36.55 | -50% |
| Current | 58x | $73.71 | — |
| Expensive | 59x | $75.21 | +2% |
Historical ranges are pointers, not guarantees.
CORT's PE is in its expensive range at 58x. If earnings grow as analysts expect, today's price would be 17x next year's earnings, in its cheap range.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over CORT in the historical PE scenario, which offers more potential upside but is not a forecast.
CORT Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect strong earnings and revenue growth for CORT, with profitability improving. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
CORT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.42 | +248% |
| Q3 2026 | $1.27 | +46% |
| Q2 2026 | $0.42 | -63% |
| Q1 2026 | $0.35 | -70% |
| Q4 2025 | $0.82 | -33% |
| Q3 2025 | $0.87 | -30% |
| Q2 2025 | $1.12 | 0% |
| Q1 2025 | $1.15 | +9.5% |
| Q4 2024 | $1.23 | +31% |
CORT earned $1.27 per share over the past year, up 46% from the year before.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over CORT on earnings, with more consistent year-over-year improvement.
CORT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $340.5M | +64% |
| Q2 2026 | $256.1M | +32% |
| Q1 2026 | $164.9M | +4.9% |
| Q4 2025 | $202.1M | +11% |
| Q3 2025 | $207.6M | +14% |
| Q2 2025 | $194.4M | +19% |
| Q1 2025 | $157.2M | +7.1% |
| Q4 2024 | $181.9M | +34% |
CORT's revenue has grown year over year for 22 quarters in a row: $340M last quarter, up 64% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | +29 points |
| Q2 2026 | 16% | +2.4 points |
| Q1 2026 | -30% | -32 points |
| Q4 2025 | 2.2% | -12 points |
| Q3 2025 | 4.9% | -21 points |
| Q2 2025 | 14% | -8 points |
| Q1 2025 | 2.2% | -18 points |
| Q4 2024 | 14% | -9.5 points |
CORT has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over CORT on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
CORT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $142.2M | +161% |
| Q2 2026 | $31M | -29% |
| Q1 2026 | -$17M | -438% |
| Q4 2025 | $38.4M | -35% |
| Q3 2025 | $54.5M | -25% |
| Q1 2025 | $5M | -79% |
| Q4 2024 | $59.2M | +905% |
| Q3 2024 | $72.2M | +37% |
CORT generated $195M in free cash flow over the past year, up 20% from the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over CORT on cash flow, with more consistent year-over-year improvement.
CORT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.1% | +4.8M shares |
| 1 year | +3.1% | +3.8M shares |
| 3 years | +11% | +12.1M shares |
| 5 years | -1.5% | -1.9M shares |
| Available history | +0.5% | +635K shares |
CORT has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $5.7M |
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | $42.5M |
| Q2 2025 | $103M |
| Q1 2025 | $27.4M |
| Q4 2024 | — |
CORT has spent almost nothing on buybacks in the past year.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
CORT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.9x | Net Cash |
| Q2 2026 | -13.2x | Net Cash |
| Q4 2025 | -2.6x | Net Cash |
| Q3 2025 | -1.9x | Net Cash |
| Q2 2025 | -1.0x | Net Cash |
| Q1 2025 | -0.8x | Net Cash |
| Q4 2024 | -0.9x | Net Cash |
| Q3 2024 | -1.0x | Net Cash |
CORT has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over CORT on leverage, with a lower net debt burden relative to earnings.
CORT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.9 | Neutral |
| Stochastic | 3.4 | Oversold |
CORT's weekly RSI is 39 (neutral) and its Stochastic is 3 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
CORT PE vs Healthcare Sector
| Metric | CORT | Sector median | Relative |
|---|---|---|---|
| PE | 58x | 26x | 125% above |
| PE % | 82 | 29 | 53 pts above |
CORT is trading at 58x earnings, a 125% premium to the Healthcare sector's median of 26x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over CORT on valuation relative to its sector.
CORT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $97.1 | 24% below |
| 20 week MA | $102.8 | 28% below |
| 50 week MA | $73.4 | 0.4% above |
| 100 week MA | $71.2 | 3.6% above |
| 200 week MA | $50.5 | 46% above |
CORT has pulled back, but its long-term trend is still up: it's below its 8- and 20-week averages, but 46% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over CORT on trend strength, trading above more of its moving averages.
CORT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $12.3 | $27.2 | +121% |
| 2021 | $27.2 | $19.9 | -27% |
| 2022 | $19.9 | $20.7 | +4% |
| 2023 | $20.7 | $32.5 | +57% |
| 2024 | $32.5 | $52.5 | +62% |
| 2025 | $52.5 | $82.7 | +58% |
| 2026 YTD | $82.7 | $73.7 | -11% |
CORT has finished higher in five of the last six years, four of them by more than 50%. It's down 11% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over CORT on returns for 2026, with the stronger performance.